Literature DB >> 31067393

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.

Piero Baglioni1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31067393     DOI： 10.1056/NEJMc1902837

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  3 in total

Review 1.  The Changing Landscape of Pharmacotherapy for Diabetes Mellitus: A Review of Cardiovascular Outcomes.

Authors:  Linda Wu; Jenny E Gunton
Journal:  Int J Mol Sci       Date:  2019-11-21       Impact factor: 5.923

Review 2.  Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19.

Authors:  Beatriz Fernandez-Fernandez; Luis D'Marco; Jose Luis Górriz; Conxita Jacobs-Cachá; Mehmet Kanbay; Sergio Luis-Lima; Esteban Porrini; Pantelis Sarafidis; María José Soler; Alberto Ortiz
Journal:  J Clin Med       Date:  2020-06-28       Impact factor: 4.241

3.  High-Dose Liraglutide and SGLT2 Inhibitor: A Promising Combination.

Authors:  Marvin Wei Jie Chua
Journal:  Clin Pract       Date:  2021-12-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.